President's Message

Welcome to Kensey Nash Corporation's website. We hope that you will spend a few minutes exploring these pages and getting to know our company. As you will see, these are exciting times for our business.

Since our founding in 1984, Kensey Nash Corporation's (KNC) focus has always been on building long-term relationships by providing quality medical products and services. We continue to accomplish this mission with groundbreaking research and innovative technology. KNC pioneered the concept of vascular closure with our Angio-Seal™ device, the market share leader now under license to St. Jude Medical. Following the successful launch of Angio-Seal™, Kensey Nash established itself as a global leader in the development and commercialization of novel resorbable products fabricated from both natural and synthetic biomaterials. Our business models for our biomaterials division range from licensing of internally developed products to contract manufacturing. To date we have launched over 300 individual products into many medical markets including orthopaedics (sports medicine, trauma, spine), dentistry, and general surgery. We also manufacture a family of innovative endovascular products, addressing vascular disease.

We have an exciting pipline of products. We are developing porcine derived extracellular matrices (ECM), materials that, when used as a scaffold for surgical applications, promote the regeneration of the tissue. ECMs are unique from other scaffold technologies in that they fundamentally change the healing process by triggering abundant new blood vessel formation and recruiting numerous cell types to the wound site. We anticipate our first ECM products will have application in general surgery (e.g., hernia repair), with marketing beginning in late fiscal 2010. We are also developing a cartilage repair device designed to repair focal defects of articular cartilage in joints. The design has a collagen-based cartilage region and a ceramic/polymer subchondral bone region based on our PTM technology. We are currently working with the US FDA to initiate a human clinical trial in the U.S.

We are extremely grateful for the commitment and strong performance of our employees and the dedication they show every day in the workplace. This enthusiasm has borne tangible results in the growth, profitability and annual strength of our company. We view this success not just as an accomplishment, but a platform to build upon.

As an industry leader, we understand the significance of our work and are proud of our contributions in providing new and innovative products that improve quality of life. At Kensey Nash Corporation, we look forward to carrying on this tradition.

Best regards,

Joseph W. Kaufmann
President and CEO